Prolight Diagnostics publishes year-end report 2022
Financial overviewFourth quarter Q4 2022 GroupFormed March 1, 2022 Other operating income amounted to kSEK 2,050. The profit after tax amounted to kSEK -2,809. Earnings per share before and after dilution: SEK -0.01. Cash flow from current operations was kSEK -5,436. Cash and cash equivalents amounted to kSEK 54,111 as of December 31, 2022. Fourth […]
Prolight Diagnostics shows proof-of-performance for high-sensitive immuno assay
Prolight Diagnostics (“Prolight”) today announced that its subsidiary Psyros Diagnostics (“Psyros”) has been able to demonstrate proof-of-performance that its high-sensitivity immunoassay is capable of reproducibly detecting low levels of specific proteins in a digital manner. “This is a very important step on our journey to develop a high-sensitivity assay for digitally detecting troponin. Such an […]
Prolight Diagnostics signs commercialisation agreement for PLD Micro Flex
Prolight Diagnostics AB today announces that it has signed a commercialisation agreement for its proprietary point-of-care (POC) platform PLD Micro Flex with its technology and development partner, The Technology Partnership plc (TTP), in Cambridge, UK. Under the agreement, TTP will pursue further development and ongoing external initiatives and discussions with the aim of securing an […]
Prolight Diagnostics AB acquires Psyros Diagnostics Ltd
Prolight Diagnostics AB has today signed an agreement to acquire UK-based Psyros Diagnostics Ltd for 65 MSEK (ca. £5.25M). Psyros Diagnostics has developed a ground-breaking single-molecule counting Point-of-Care (POC) technology. This patent-pending and multiplex-capable technology enables the measurement of biomarkers at extremely low concentrations (femtomolar 10-15) in approximately 10 minutes or less. “To our knowledge, […]
